Early prenatal androgenization RESULTS: In diminished ovarian reserve in adult female rhesus monkeys

Human Reproduction

Volumn 24, Issue 12, 2009, Pages 3188-3195

  Dumesic, D A ^a,b   Patankar, M S ^b,c   Barnett, D K ^a,c   Lesnick, T G ^d   Hutcherson, B A ^c   Abbott, D H ^a,b,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Aging; Anti Mullerian hormone; IVF; Ovarian reserve; Prenatal androgens

Indexed keywords

ANDROGEN; ANDROSTANOLONE; FOLLITROPIN; GONADOTROPIN; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; PROGESTERONE; RECOMBINANT FOLLITROPIN; STEROID; TESTOSTERONE;

AGE; ANIMAL EXPERIMENT; ANOVULATION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EPIGENETICS; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; FETUS DEVELOPMENT; GESTATION PERIOD; GONADOTROPIN BLOOD LEVEL; MENSTRUAL CYCLE; NONHUMAN; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY FOLLICLE DEVELOPMENT; PRENATAL PERIOD; RHESUS MONKEY; STEROID BLOOD LEVEL; VIRILIZATION;

ANIMALIA; MACACA MULATTA;

EID: 72949087329     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dep324     Document Type: Article

References (61)

1. Abbott DH, Dumesic DA, Eisner JR, Colman RJ, KemnitzJW. Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab 1998;9:62-67.
2. Abbott DH, Colman RJ, Kemnitz JW, Eisner JR, Dumesic DA. Prenatal androgen excess programs for polycystic ovarian syndrome in female rhesus monkeys. In: Chang J, Heindel JJ, Dunaif A (eds). Polycystic Ovary Syndrome. New York: Marcel Dekker Inc, 2002, 119-133.
3. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 2005; 11:357-374.
4. Abbott DH, Bruns CM, Barnett DK, Dumesic DA. Fetal programming of polycystic ovary syndrome. In: Kovacs G, Norman R (eds). Polycystic Ovary Syndrome, 2nd edn. Cambridge: Cambridge University Press, 2007, 262-287.
5. Abbott DH, Barnett DK, Levine JE, Padmanabhan V, Dumesic DA, Jacoris S, Tarantal AF. Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. Biol Reprod 2008;79:154-163.
6. Abbott DH, Tarantal AF, Dumesic DA. Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol 2009;71:1-9.
7. Al-Qahtani A, Muttukrishna S, Appasamy M, Johns J, Cranfield M, Visser JA, Themmen AP, Groome NP. Development of a sensitive enzyme immunoassay for anti-Mullerian hormone and the evaluation of potential clinical applications in males and females. Clin Endocrinol (Oxf) 2005;63:267-273.
8. Appt SE, Clarkson TB, Chen H, Adams MR, Christian PJ, Hoyer PB, Wilson ME, Kaplan JR Serum antimullerian hormone predicts ovarian reserve in a monkey model. Menopause 2009;16:597-601.
9. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, Rosenthal IM. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994; 79:1328-1333.
10. Bavister BD, Boatman DE, Leibfried LM, Loose M, Vernon MW. Fertilization and cleavage of rhesus monkey oocytes in vitro. Biol Reprod 1983;28:983-999.
11. Burger HG, Hale GE, Robertson DM, Dennerste L A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update 2007;13:559-565.
12. Catteau-Jonard S, Pigny P, Reyss AC, Decanter C, Poncelet E, Dewailly D. Changes in serum antimullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92: 4138-4143.
13. Chen MJ, YangWS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008;23:952-957.
14. Colman RJ, Anderson R. Nonhuman primate calorie restriction. Antioxid Redox Signal, in press.
15. Crisosto N, Codner E, Maliqueo M, Echiburu B, Sanchez F, Cassorla F, Sir-Petermann T. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2739-2743. (Pubitemid 47037384)
16. Dailey RA, Neill JD. Seasonal variation in reproductive hormones of rhesus monkeys: anovulatory and short luteal phase menstrual cycles. Biol Reprod 1981;25:560-567.
17. Downs JL, Urbanski HF. Neuroendocrine changes in the aging reproductive axis of female rhesus macaques (Macaca mulatto). Biol Reprod 2006;75:539-546.
18. Dumesic DA, Schramm RD, Peterson E, Paprocki AM, Zhou R, Abbott DH. Impaired developmental competence of oocytes in adult prenatally androgenized female Rhesus monkeys undergoing gonadotropin stimulation for in vitro fertilization. J Clin Endocrinol Metab 2002;87:1111-1119.
19. Dumesic DA, Schramm RD, Bird IM, Peterson E, Paprocki AM, Zhou R, Abbott DH. Reduced intrafollicular androstenedione and estradiol levels in early-treated prenatally androgenized female rhesus monkeys receiving FSH therapy for in vitro fertilization. Biol Reprod 2003; 69:1213-1219.
20. Dumesic DA, Abbott DH, Padmanabhan V. PCOS and its developmental origins. Rev Endocr Metab Disord 2007;8:127-141.
21. Dumesic DA, Lesnick TG, Stassart JP, Ball GD, Wong A, Abbott DH. Intrafollicular antimullerian hormone (AMH) levels predict follicle responsiveness to FSH1n normoandrogenic ovulatory women undergoing GnRH analog/recombinant human FSH therapy for IVF-ET. Fertil Steril 2009;92:217-221.
22. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of antimullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006;21: 2022-2026.
23. Eisner JR, Barnett MA, Dumesic DA, Abbott DH. Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil Steril 2002;77:167-172.
24. Eldar-Geva T, Margalioth EJ, Gal M, Ben-Chetrit A, Algur N, Zylber-Haran E, Brooks B, Huerta M, Spitz IM. Serum antimullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005;20:1814-1819.
25. Elder K, Mathews T, Kutner E, Kim E, Espenberg D, Faddy M, Gosden R. Impact of gonadotrophin stimulation for assisted reproductive technology on ovarian ageing and menopause. Reprod Biomed Online 2008; 16:611-616.
26. Elting MW, Kwee J, Korsen TJM, Rekers-Mombarg LTM, Schoemaker J. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 2003;79:1154-1160.
27. Foong SC, Abbott DH, Lesnick TG, Session DR, Walker DL, Dumesic DA. Diminished intrafollicular estradiol (E2) levels in women with reduced ovarian responsiveness to recombinant human follicle stimulating hormone (FSH) therapy for in vitro fertilization (IVF). Ferti1 Steril 2005;83:1377-1383.
28. Foong SC, Abbott DH, Zschunke MA, Lesnick TG, Phy JL, Dumesic DA. Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome (PCOS) patients undergoing gonadotropin therapy for in vitro fertilization. J Clin Endocrinol Metab 2006;91:2327-2333.
29. Gardner DK, Lane M. Culture and selection of viable blastocysts: a feasible proposition for human IVF? Hum Reprod Update 1997;3:367-382.
30. Goy RW, Robinson JA Prenatal exposure of rhesus monkeys to patent androgens: morphological, behavioral, and physiological consequences. Banbury Rep 1982;11:355-378.
31. Goy RW, Kemnitz JW. Early, persistent and delayed effects of virilizing substances delivered transplacental^ to female rhesus monkeys. In: Zbinden G, Cuomo V, Racagni G, Weiss B (eds). Applications of Behavioral Pharmacology in Toxicology. New York: Raven Press, 1983, 303-314.
32. Hagenfeldt K, Janson PO, Holmdahl G, Falhammar H, Filipsson H, Frisen L, Thoren M, Nordenskjold A. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2008;23:1607-1613.
33. Klein NA, Soules MR. Endocrine changes of the perimenopause. Clin Obstet Gynecol 1998;41:912-920.
34. Knight PG, Glister C. Local roles of TGF-fS superfamily members in the control of ovarian follicle development. Anim Reprod Sci 2003; 78:165-183.
35. Laven JSE, Mulders AGMGJ, Visser JA, Themmen AP, de Jong FH, Fauser BCJM. Antimullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318-323.
36. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, MacLaughlin DT Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996;81:571-576.
37. Merke DP, Cutler GB Jr. New ideas for medical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001 ;30:121-135.
38. Nelson VL, Legro RS, Strauss JF III, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycysitc ovaries. Mol Endocrinol 1999;13:946-957.
39. Nelson VL, Qin K, Rosenfield RL, Wood JR, Penning TM, Legro RS, Strauss JF III, McAllister JM. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001 ;86:5925-5933.
40. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 2007; 22:2414-2421.
41. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-697.
42. Nusser KD, Mitalipov S, Widmann A, Gerami-Naini B, Yeoman RR, Wolf DP. Developmental competence of oocytes after ICSI in the rhesus monkey. Hum Reprod 2001; 16:130-137. (Pubitemid 32058594)
43. Pellatt L, Hanna L, Brincat M, Galae R, Brain H, Whitehead S, Mason H. Granulosa cell production of antimullerian hormone is increased in polycystic ovaries. J Clin Endocinol Metab 2007;92:240-245.
44. Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941-945. (Pubitemid 43357762)
45. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20:1820-1826.
46. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Antimullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship witH1ncreased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296:E238-E243.
47. Rajpert-De Meyts E, Orgensen N, Graem N, Muller J, Cate RL, Skakkebaek NE. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 1999; 84:3836-3844.
48. Resko JA, Ellinwood WE. Sexual differentiation of the brain of primates. In: Serio M, Motta M, Zanisi M, Martini L (eds). Sexual Differentiation: Basic and Clinical Aspects. New York: Raven Press, 1984, 169-181.
49. Resko JA, Buhl AE, Phoenix CH. Treatment of pregnant rhesus macaques with testosterone propionate: observations on its fate in the fetus. Biol Reprod 1987;37:1185-1191.
50. Seifer DB, MacLaughlin DT. Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril 2007; 88:539-546.
51. Sokal RR, Rohlf FJ. Biometry, The Principles and Practice of Statistics in Biological Research, 3rd edn. New York: WH Freeman and Co, 1995, 413-422.
52. Steckler T, Wang J, Bartol FF, Roy SK, Padmanabhan V. Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology 2005; 146:3185-3193.
53. Stikkelbroeck NM, Hermus AR, Braat DD, Otten BJ. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Obstet Gynecol Surv 2003;58:275-284.
54. Thornton J, Zehr JL, Loose MD. Effects of prenatal androgens on rhesus monkeys: a model system to explore the organizational hypothesis in primates. Horm Behav 2009;55:633-645.
55. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA Androgens stimulate early stages of follicle growtH1n the primate ovary. J Clin Invest 1998;101:2622-2629.
56. Vendola K, Zhou J, Wang J, Bondy CA. Androgens promote insulin-like growth factor-l and insulin-like growth factor-l receptor gene expression in the primate ovary. Hum Reprod 1999a; 14:2328-2332. (Pubitemid 29425423)
57. Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 1999b;61:353-357. (Pubitemid 29344748)
58. Visser JA, Durlinger ALL, Peters IJJ, van den Heuvel ER, Rose UM, Kramer P, de Jong FH, Themmen APN. Increased oocyte degeneration and follicular atresia during the estrus cycle in anti-mullerian hormone null mice. Endocrinology 2007; 148:2301-2308.
59. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BCJM, Themmen APN. Anti-mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83.
60. Weil SJ, Vendola K, Zhou J, Adesanya OO, WangJ, OkaforJ, Bondy CA. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998;83:2479-2485.
61. Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999;84:2951-2956.